New technologies for nephron-sparing surgery in upper urinary tract cancers.
暂无分享,去创建一个
[1] F. Algaba,et al. Long-term Oncologic Outcomes of Endoscopic Management of High-risk Upper Tract Urothelial Carcinoma: The Fundació Puigvert's Experience. , 2023, Journal of endourology.
[2] J. Huguet,et al. Manejo del carcinoma in situ de tramo urinario superior diagnosticado por biopsia ureteroscópica: ¿es el bacilo de Calmette-Guérin una alternativa a la nefroureterectomía? , 2023, Actas Urológicas Españolas.
[3] A. Masson-Lecomte,et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. , 2023, European urology.
[4] S. Shariat,et al. A Review of How Lasers Are Used in UTUC Surgery: Can the Choice of Laser Affect Outcomes? , 2023, Cancers.
[5] F. Sánchez-Margallo,et al. Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma. , 2023, Minerva urology and nephrology.
[6] Y. Lotan,et al. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma , 2023, The Journal of urology.
[7] S. Di Pietro,et al. Effectiveness and Safety of Thulium Fiber Laser in the Conservative Management of Patients with Upper Tract Urothelial Carcinoma , 2022, European urology open science.
[8] M. Humphreys,et al. Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi‐institutional retrospective cohort study , 2022, BJU international.
[9] F. Sánchez-Margallo,et al. Cytotoxicity Assessment of a New Design for a Biodegradable Ureteral Mitomycin Drug-Eluting Stent in Urothelial Carcinoma Cell Culture , 2022, Polymers.
[10] S. Aznar-Cervantes,et al. Assessment of a Coated Mitomycin-Releasing Biodegradable Ureteral Stent as an Adjuvant Therapy in Upper Urothelial Carcinoma: A Comparative In Vitro Study , 2022, Polymers.
[11] S. Anai,et al. A prospective, single-arm trial of fluorescent ureteroscopy-assisted thulium-holmium:YAG dual laser ablation for upper urinary tract cancer: Study protocol of the FLUAM trial , 2022, Contemporary clinical trials communications.
[12] Katie S. Murray,et al. Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience , 2022, The Journal of urology.
[13] D. Lifshitz,et al. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report , 2021, The Journal of urology.
[14] A. Masson-Lecomte,et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). , 2021, European urology.
[15] A. Breda,et al. Endoscopic management of upper urinary tract urothelial carcinoma: oncologic outcomes and prognostic factors in a contemporary cohort. , 2021, Journal of endourology.
[16] B. Eisner,et al. Conservative treatment of upper urinary tract carcinoma in patients with imperative indications , 2021 .
[17] T. Matsuda,et al. Photodynamic Diagnosis–guided Dual Laser Ablation for Upper Urinary Tract Carcinoma: Preoperative Preparation, Surgical Technique, and Clinical Outcomes , 2021, European urology open science.
[18] A. Shabsigh,et al. Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma , 2021, Cancer Chemotherapy and Pharmacology.
[19] A. Gözen,et al. Thulium-laser retrograde intra renal ablation of upper urinary tract transitional cell carcinoma: an ESUT Study , 2021 .
[20] Masami Watanabe,et al. Photodynamic diagnostic ureteroscopy using the VISERA ELITE video system for diagnosis of upper-urinary tract urothelial carcinoma: a prospective cohort pilot study , 2021, BMC Urology.
[21] M. Gleave,et al. A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma. , 2020, Urologic oncology.
[22] E. Emiliani,et al. The Impact of Ureteroscopy following Computed Tomography Urography in the Management of Upper Tract Urothelial Carcinoma. , 2020, The Journal of urology.
[23] A. Breda,et al. Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: Systematic review and meta-analysis. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[24] D. Lifshitz,et al. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. , 2020, The Lancet. Oncology.
[25] B. Becker,et al. Comparative analysis of vaporization and coagulation properties of a hybrid laser (combination of a thulium and blue diode laser) vs. thulium and Ho:YAG lasers: potential applications in endoscopic enucleation of the prostate (EEP). , 2020, Journal of endourology.
[26] F. Regis,et al. Adjuvant single-dose upper urinary tract instillation of mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: a single-centre prospective non-randomized trial. , 2020, Journal of endourology.
[27] M. Furihata,et al. 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence ureterorenoscopy for urinary upper tract urothelial carcinoma ∼Preliminary prospective single centre trial∼. , 2019, Photodiagnosis and photodynamic therapy.
[28] B. Becker,et al. Effect of optical fiber diameter and laser emission mode (cw vs pulse) on tissue damage profile using 1.94 µm Tm:fiber lasers in a porcine kidney model , 2019, World Journal of Urology.
[29] S. Shariat,et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis , 2019, World Journal of Urology.
[30] A. Breda,et al. Comparison of biopsy devices in upper tract urothelial carcinoma , 2018, World Journal of Urology.
[31] E. Messing,et al. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial , 2018, JAMA.
[32] C. Wood,et al. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. , 2017, Journal of endourology.
[33] Elsawi Osman,et al. Photodynamic diagnosis in upper urinary tract urothelial carcinoma: A systematic review , 2017, Arab journal of urology.
[34] V. Margulis,et al. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma , 2017, World Journal of Urology.
[35] M. Babjuk,et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. , 2016, European urology.
[36] R. Reis,et al. Drug-eluting biodegradable ureteral stent: New approach for urothelial tumors of upper urinary tract cancer. , 2016, International journal of pharmaceutics.
[37] A. Abbruzzese,et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] A. Lenis,et al. Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. , 2017, Urology.